HK Stock Market Move | SIMCERE PHARMA (02096) opened nearly 5% higher after reaching a $1.53 billion licensing partnership with Roche for the tri-specific antibody SIM0660.

SIMCERE PHARMA (02096) opened nearly 5% higher and, as of the time of writing, has risen 4.82% to HKD 11.52, with a transaction volume of HKD 1.8893 million. In terms of news, SIMCERE PHARMA announced that it has signed an exclusive licensing agreement with Roche for the global development and commercialization of the CD79a/CD19/CD3 tri-specific antibody SIM0660, with a potential value exceeding USD 1.53 billion. This deal was signed by SIMCERE PHARMA's oncology innovation drug company, Transcenta. According to the agreement, Roche will obtain exclusive rights for the development, production, and commercialization of SIM0660 worldwide. It is reported that SIM0660 is a tri-specific antibody developed using Transcenta's T-cell engager (TCE) multi-specific antibody technology platform. This molecule will combine the T-cell engaging arm targeting CD3 with binding domains targeting two B-cell antigens, CD79a and CD19, inducing strong T-cell-mediated cytotoxic effects while effectively limiting cytokine release. To date, SIMCERE PHARMA Group has completed six external authorizations, with a total potential transaction value exceeding USD 6.1 billion.